A multicenter, open-label, phase III study of Abcertin in Gaucher disease

@article{Lee2017AMO,
  title={A multicenter, open-label, phase III study of Abcertin in Gaucher disease},
  author={B. Lee and A. Abdalla and J. Choi and A. Beshlawy and G. Kim and S. Heo and A. Megahed and M. A. Elsayed and Tarik Barakat and Khaled M. Eid and Mona Eltagui and M. M. Mahmoud and E. Fateen and June-Young Park and Han-Wook Yoo},
  journal={Medicine},
  year={2017},
  volume={96}
}
  • B. Lee, A. Abdalla, +12 authors Han-Wook Yoo
  • Published 2017
  • Medicine
  • Medicine
    • Background: Gaucher disease (GD) is caused by a deficiency in the lysosomal enzyme glucocerebrosidase. Enzyme replacement therapy (ERT) is recommended for clinical improvement. Methods: The efficacy and safety of a new imiglucerase, Abcertin, were assessed in 7 Egyptian patients with treatment-naïve type 1 GD. Each patient was administered a biweekly 60 U/kg dose of Abcertin for 6 months. The primary endpoint was the change in hemoglobin concentration. The secondary endpoints were changes from… CONTINUE READING
    View on Wolters Kluwer
    doi.org
    3 Citations
    Background Citations
    1
    Methods Citations
    1
    3 Citations
    Citation Type

    Citation Type

    Current and Emerging Pharmacotherapy for Gaucher Disease
    • P. Giraldo
    • Medicine
    • Clinical Reviews in Bone and Mineral Metabolism
    • 2019
    The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
    Lysosomes as a therapeutic target
    • 33
    • PDF

    References

    SHOWING 1-10 OF 22 REFERENCES
    A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease
    • 8
    • PDF
    Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment
    • 23
    • PDF
    Replacement therapy with imiglucerase for type 1 Gaucher's disease
    • 101
    Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    • 1,081
    Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model
    • 37
    • PDF
    Enzyme Therapy in Type 1 Gaucher Disease: Comparative Efficacy of Mannose-Terminated Glucocerebrosidase from Natural and Recombinant Sources
    • 404
    Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience.
    • 106
    Individualization of long-term enzyme replacement therapy for Gaucher disease
    • 105
    • PDF
    Revised recommendations for the management of Gaucher disease in children
    • 65
    The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    • 106